1-20 of 28 results for subject:Cancer
Librarians' tools
- Search time
- 0.29 seconds
- Solr query time
- 0.006 seconds
- Search query
- subject:Cancer
- We searched for
- subject_t:Cancer OR subject_t:Oncology OR subject_t:Sarcoma OR subject_ses:8937
Type
House
Session
Year
Department
Member
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the effectiveness of the NHS England Help Us Help You campaign on cancer symptom awareness.
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the effectiveness of the NHS England Help Us Help You campaign on cancer symptom awareness.
The Department and NHS England recognise the importance of directly targeting awareness campaigns at areas that we know will make a difference, to increase awareness of cancer symptoms and encourage people to get checked.
NHS England runs Help Us Help You campaigns to increase knowledge of cancer symptoms and to address the barriers to acting on them, to encourage people to come forward as soon as possible to see their general practitioner. The campaigns are evaluated in line with best practice, considering media metrics, campaign awareness, understanding and intention to act, along with analysis of operational data.
The most recent phases of Help Us Help You, which ran between January and March 2025, saw increases in symptom knowledge and intention to act. NHS England is undertaking operational data analysis, with early data showing an increase in cancer diagnosis at the same time as campaign activity. The campaigns focus on a range of symptoms, as well as encouraging body awareness to help people spot symptoms across a wide range of cancers at an earlier point.
To ask the Secretary of State for Health and Social Care, what her timetable is for the introduction of the recommendations of the final evaluation report for the secondary care routine reflux cohort of the Cytosponge test.
To ask the Secretary of State for Health and Social Care, what her timetable is for the introduction of the recommendations of the final evaluation report for the secondary care routine reflux cohort of the Cytosponge test.
On 26 February 2024, NHS England published the results of the cytosponge test pilot for secondary care routine reflux and Barrett’s surveillance cohort, which began in January 2021, and launched at 30 hospitals across England. The pilot tested over 8,500 patients with the capsule sponge test. Evaluation of a cohort of patients showed almost eight out of 10 patients, who completed a test, were discharged without the need for further testing, freeing up endoscopy capacity for higher risk patients and those referred for urgent tests for oesophageal cancer. Patients with positive results from the capsule sponge test who were referred on for an endoscopy had the highest prevalence of Barrett’s oesophagus, at 27.2%, compared to zero patients with negative results who completed an endoscopy.
A timetable for the introduction of the recommendations of the final evaluation report for the secondary care routine reflux cohort of the cytosponge test, is yet to be finalised and published.
To ask the Secretary of State for Health and Social Care, when he plans to publish the final evaluation report for the secondary care routine reflux cohort of the Cytosponge test.
To ask the Secretary of State for Health and Social Care, when he plans to publish the final evaluation report for the secondary care routine reflux cohort of the Cytosponge test.
NHS England is currently finalising and approving the evaluation report before publication. Once approved the report will be published.
To ask the Secretary of State for Health and Social Care, if he will hold discussions with health ministers in (a) Scotland, (b) Wales and (c) Northern Ireland on reaching a consensus on having 75 per cent of cancers diagnosed within the first two stages across the UK.
To ask the Secretary of State for Health and Social Care, if he will hold discussions with health ministers in (a) Scotland, (b) Wales and (c) Northern Ireland on reaching a consensus on having 75 per cent of cancers diagnosed within the first two stages across the UK.
We have no current plans to do so. While the NHS Long Term Plan commits to diagnosing 75% of cancers in England at an early stage by 2028, in other parts of the United Kingdom this is a devolved matter. The Department engages in sharing best practice between the devolved administrations.
To ask the Secretary of State for Health and Social Care, when NICE plans to publish the outcome of its assessment of the effectiveness of Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer.
To ask the Secretary of State for Health and Social Care, when NICE plans to publish the outcome of its assessment of the effectiveness of Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer.
In February 2021, the National Institute for Health and Care Excellence issued final guidance that recommends niraparib for use within the Cancer Drugs Fund (CDF) for the maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. Niraparib is now available to eligible National Health Service patients in England through the CDF in line with this recommendation.
To ask the Secretary of State for Health and Social Care, whether it remains his policy increase diagnosis of the 10 most common cancers at stages 1 and 2 to 75 percent by 2028.
To ask the Secretary of State for Health and Social Care, whether it remains his policy increase diagnosis of the 10 most common cancers at stages 1 and 2 to 75 percent by 2028.
The NHS Long Term Plan commitments remain in place despite the COVID-19 pandemic. This includes the commitment of staging 75% of all cancers at stage 1 or 2.
To ask the Chancellor of the Duchy of Lancaster and Minister for the Cabinet Office, what the daily death rate was from (a) cancer, (b) dementia (c) Alzheimer's disease, (d) coronary heart disease, (e) stroke and (f) covid-19 in the latest period for which figures are available.
To ask the Chancellor of the Duchy of Lancaster and Minister for the Cabinet Office, what the daily death rate was from (a) cancer, (b) dementia (c) Alzheimer's disease, (d) coronary heart disease, (e) stroke and (f) covid-19 in the latest period for which figures are available.
The information requested falls under the remit of the UK Statistics Authority. I have therefore asked the Authority to respond.
To ask the Chancellor of the Duchy of Lancaster and Minister for the Cabinet Office, how many people died from (a) coronary heart disease, (b) stroke, (c) prostate cancer, (d) breast cancer and (e) bowel cancer from 1 April to 1 August in (i) 2016, (ii) 2017, (iii) 2018, (iv)...
To ask the Chancellor of the Duchy of Lancaster and Minister for the Cabinet Office, how many people died from (a) coronary heart disease, (b) stroke, (c) prostate cancer, (d) breast cancer and (e) bowel cancer from 1 April to 1 August in (i) 2016, (ii) 2017, (iii) 2018, (iv)...
The information requested falls under the remit of the UK Statistics Authority. I have therefore asked the Authority to respond.
To ask the Secretary of State for Health and Social Care, with reference to the news story entitled, Early cancer detection and survival to be prioritised by NHS, published by his Department in July 2019, if he will make it his policy to publish regular progress reports on the Government's...
To ask the Secretary of State for Health and Social Care, with reference to the news story entitled, Early cancer detection and survival to be prioritised by NHS, published by his Department in July 2019, if he will make it his policy to publish regular progress reports on the Government's...
The National Cancer Registration and Analysis Service (NCRAS) are currently developing a new early diagnosis metric which will be used specifically to track progress towards the 75% ambition. This new metric will provide a more comprehensive measure of early diagnosis, including more cancer sites than the current available measures.
This metric will be regularly reported on the NCRAS website.
To ask the Secretary of State for Health and Social Care, if he will hold discussions with his counterparts in the devolved regions on recent changes in rates of cancer involving children to ensure reductions in all parts of the UK.
To ask the Secretary of State for Health and Social Care, if he will hold discussions with his counterparts in the devolved regions on recent changes in rates of cancer involving children to ensure reductions in all parts of the UK.
Health and social care, including cancer treatment and care, is a devolved matter. As such, no discussions are currently planned.
To ask the Secretary of State for Health and Social Care, if he will hold discussions with his counterparts in the devolved administrations on the variation in rates of children diagnosed with cancer across the UK.
To ask the Secretary of State for Health and Social Care, if he will hold discussions with his counterparts in the devolved administrations on the variation in rates of children diagnosed with cancer across the UK.
No such discussions are planned. NHS England is currently out to consultation on new service specifications for children's cancer services in England. Further information is available at the following link:
https://www.engage.england.nhs.uk/consultation/childrens-cancer-services
The consultation closes on 4 August 2019.
To ask the Minister for the Cabinet Office, what the change has been in the ratio per thousand of population of (a) male and (b) female children diagnosed with cancer in the UK between (a) 2008 and (b) 2018.
To ask the Minister for the Cabinet Office, what the change has been in the ratio per thousand of population of (a) male and (b) female children diagnosed with cancer in the UK between (a) 2008 and (b) 2018.
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.
To ask the Chancellor of the Exchequer, what (a) financial and (b) other support the Government makes available to people diagnosed with cancer who have (i) banking and (ii) other financial problems.
To ask the Chancellor of the Exchequer, what (a) financial and (b) other support the Government makes available to people diagnosed with cancer who have (i) banking and (ii) other financial problems.
The Government set up the Money Advice Service (MAS) to provide free-to-use financial guidance for all consumers, whatever their circumstances. Moving forward, the Government has legislated to merge the functions of MAS with those of The Pensions Advisory Service (TPAS) and Pension Wise, to create a Single Financial Guidance Body, which will simplify the existing public financial guidance landscape.
The Government has also implemented a regulatory framework for financial services that ensures firms give support to vulnerable consumers, such as people diagnosed with cancer who have banking and other financial problems. The Financial Conduct Authority has a statutory objective to protect consumers and its Principles for Business require firms to pay due regard to the interests of its customers and treat them fairly.
The Government supports ongoing FCA work to make help available to vulnerable customers, such as the publication by banks of a list of additional services they offer customers, including specialist cancer support services.
To ask the Minister for the Cabinet Office, what the five most common cancer diagnoses were among (a) men and (b) women in (i) 2007 and (ii) 2017.
To ask the Minister for the Cabinet Office, what the five most common cancer diagnoses were among (a) men and (b) women in (i) 2007 and (ii) 2017.
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.
To ask the Minister for the Cabinet Office, what the top five cancer diagnoses were among (a) men and (b) women in (i) 2007 and (ii) 2017.
To ask the Minister for the Cabinet Office, what the top five cancer diagnoses were among (a) men and (b) women in (i) 2007 and (ii) 2017.
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.
To ask the Minister for the Cabinet Office, what the five most common cancer diagnoses were among (a) men and (b) women in (i) 2007 and (ii) 2017.
To ask the Minister for the Cabinet Office, what the five most common cancer diagnoses were among (a) men and (b) women in (i) 2007 and (ii) 2017.
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.
To ask the Minister for the Cabinet Office, what the five most common cancer diagnoses were among (a) men and (b) women in (i) 2007 and (ii) 2017.
To ask the Minister for the Cabinet Office, what the five most common cancer diagnoses were among (a) men and (b) women in (i) 2007 and (ii) 2017.
The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the instances of childhood obesity being the primary cause of cancer among children aged 16 and under, in each of the last 10 years.
To ask the Secretary of State for Health and Social Care, what estimate he has made of the instances of childhood obesity being the primary cause of cancer among children aged 16 and under, in each of the last 10 years.
No such estimate has been made.
To ask the Secretary of State for Health, with reference to the Answer of 26 November 2014 to Question 215220, what information his Department holds on further research on the use of dogs to detect cancer.
To ask the Secretary of State for Health, with reference to the Answer of 26 November 2014 to Question 215220, what information his Department holds on further research on the use of dogs to detect cancer.
The National Institute for Health Research (NIHR) Clinical Research Network is recruiting to a study of canine olfactory detection of human urological cancer from the odour of human urine samples. The study is funded by the charity Medical Detection Dogs.
The NIHR is funding a programme of systematic reviews to determine the accuracy of tests for the diagnosis and staging of skin cancer. The report from this programme is expected to be published in December 2017. One of the ongoing reviews funded within the programme is on canine odour detection for the diagnosis of cutaneous melanoma in adults.
To ask the Secretary of State for Health, if he will take steps to expedite the provision through the NHS of immunotherapy treatments for cancer; and if he will make a statement.
To ask the Secretary of State for Health, if he will take steps to expedite the provision through the NHS of immunotherapy treatments for cancer; and if he will make a statement.
A number of immunotherapy drugs are licensed for the treatment of different cancers and are available for use on the National Health Service, subject to funding decisions by the relevant commissioner. Pembrolizumab and nivolumab are two new immunotherapies that are able to treat a number of cancers. The first cancer where these medicines have shown significant increase in patient survival is advanced stage of melanoma. The Medicines and Healthcare products Regulatory Agency has issued early access scientific opinions for both products for treatment of advanced stage melanoma. The Early Access to Medicines scientific opinion for pembrolizumab (Merck Sharp & Dohme) was issued in March 2015 and that for nivolumab (Bristol Myers Squibb) in May 2015.
Applications for marketing authorisations for both products have already received positive opinions from the European Medicines Agency and marketing authorisations are anticipated to be issued by the European Commission soon.
Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) has been able to recommend a number of immunotherapy treatments including, ipilimumab and obinutuzumab. NICE is currently developing technology appraisal guidance on other immunotherapy treatments including nivolumab and pembrolizumab. Wherever possible, NICE aims to publish draft or final guidance on drugs referred to it within a few months of the drug receiving a license. NHS commissioners are legally required to fund drugs and treatments recommended in NICE technology appraisal guidance.